Quidelortho CORP Form 4 insider transactions

QuidelOrtho's Chief Financial Officer, Joseph M. Busky, filed an amended Form 4 to correct the reported purchase price of 3,370 shares of common stock.

QuidelOrtho Corp Director Matthew Strobeck plans to acquire 10,000 shares of common stock at an average price of $23.9586 per share on February 13, 2026, under a Rule 10b5-1 plan.

QuidelOrtho's CFO, Joseph M. Busky, reported planned acquisitions and dispositions of common stock under a Rule 10b5-1 plan, effective February 13, 2026.

QuidelOrtho Corp's President and CEO, Brian J. Blaser, has filed a Form 4 indicating a planned future purchase of 10,540 shares of common stock.

QuidelOrtho Chief Legal Officer Michelle A. Hodges reported the vesting of restricted stock units and subsequent share disposition for tax obligations.

QuidelOrtho's Chief Financial Officer, Joseph M. Busky, reported the vesting of restricted stock units and subsequent share disposition for tax obligations.

Ronald Lee Bowman, QuidelOrtho's Chief Human Resources Officer, received grants of restricted stock units and non-qualified stock options.

QuidelOrtho's Chief Operations Officer, Philip D. McLellan, reported the acquisition of new restricted stock units and stock options, alongside the vesting and tax-related disposition of previously granted equity.

QuidelOrtho's EVP of R&D & CTO, Jonathan Philip Siegrist, received significant equity awards, including restricted stock units and stock options, on January 30, 2026.

QuidelOrtho's Chief Legal Officer, Michelle A. Hodges, reported the acquisition of common stock from restricted stock unit releases and non-qualified stock options, alongside dispositions for tax obligations.

QuidelOrtho Corporation's Chief Financial Officer, Joseph M. Busky, was granted 29,444 restricted stock units, vesting over three years.

QuidelOrtho Corporation's President and CEO, Brian J. Blaser, was granted 213,470 restricted stock units, vesting over three years.

QuidelOrtho's EVP of R&D & CTO, Jonathan Philip Siegrist, reported the vesting of 2,448 restricted stock units and a subsequent sale of 1,009 shares for tax obligations.

QuidelOrtho's Chief Operations Officer, Philip D. McLellan, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

QuidelOrtho's Chief Legal Officer, Michelle A. Hodges, reported the vesting of restricted stock units and associated tax withholding, alongside an Employee Stock Purchase Plan acquisition.

QuidelOrtho's Chief Human Resources Officer, Ronald Lee Bowman, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

QuidelOrtho's Chief Financial Officer, Joseph M. Busky, reported the vesting of restricted stock units and a subsequent tax-related sale of shares.

QuidelOrtho Corp's President and CEO, Brian J. Blaser, reported the vesting of 21,446 restricted stock units and the subsequent disposition of 7,755 shares for tax obligations.

Ann D. Rhoads, a Director at QuidelOrtho Corp, purchased 750 shares of common stock at $28.275 per share, increasing her direct beneficial ownership.

QuidelOrtho Corp Director Joseph D. Wilkins Jr. purchased 370 shares of common stock at $27.955 per share, increasing his direct beneficial ownership.

QuidelOrtho Corp Director Kenneth J. Widder exercised stock options and subsequently sold a portion of his common stock holdings on November 25, 2025.

QuidelOrtho Corp's Chief Financial Officer, Joseph M. Busky, purchased 4,770 shares of common stock, signaling management confidence.

QuidelOrtho Corp Director Mary Lake Polan, Ph.D. acquired 1,000 shares of common stock at $22.43 per share.

QuidelOrtho's Chief Legal Officer, Michelle A. Hodges, reported the vesting of restricted stock units and subsequent share disposition for tax obligations.

QuidelOrtho Corp's President and CEO, Brian J. Blaser, filed a Form 4 indicating a planned future acquisition of 23,500 common shares through a trust.

QuidelOrtho's EVP of R&D & CTO, Jonathan Siegrist, acquired 18,656 common shares through RSU vesting and sold 6,676 shares to cover tax obligations.

QuidelOrtho's Chief Legal Officer, Michelle A. Hodges, reported the vesting of 390 restricted stock units and the subsequent sale of 199 shares to cover tax obligations.

QuidelOrtho's Chief Human Resources Officer, Ronald Lee Bowman, reported the vesting of 2,565 restricted stock units and the subsequent sale of 918 shares for tax obligations.

Kenneth F. Buechler, a Director at QuidelOrtho Corp, exercised non-qualified stock options to acquire 9,215 shares of common stock at an exercise price of $15.74 per share.

Michelle A. Hodges, Chief Legal Officer of QuidelOrtho Corp, reported the vesting of 11,873 restricted stock units and a subsequent disposition of 6,030 shares for tax withholding purposes.